SecSonar.com

Glaukos Corporation (GKOS)

Glaukos Corporation at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Glaukos Corporation (GKOS) is a Medical - Devices company based in US with a market capitalization of $6.1B. Revenue grew 32.3% year-over-year and free cash flow was negative at -$54M. This page tracks GKOS's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 995 employees · IPO Jun 25, 2015

Valuation

Valuation & price

$144.01 · as of May 17, 2026 · -2.9% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

9.35

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$148$112$75.26Jul 25Dec 25Jul 26Jul 7, 25$101.46Jul 9, 25$104.72Jul 11, 25$103.81Jul 15, 25$98.26Jul 17, 25$99.00Jul 21, 25$96.73Jul 23, 25$96.00Jul 25, 25$94.30Jul 29, 25$93.76Jul 31, 25$86.09Aug 4, 25$87.50Aug 6, 25$88.49Aug 11, 25$87.02Aug 13, 25$91.79Aug 15, 25$89.86Aug 19, 25$91.03Aug 21, 25$89.79Aug 25, 25$91.55Aug 27, 25$95.12Aug 29, 25$95.82Sep 3, 25$94.47Sep 5, 25$93.94Sep 9, 25$90.91Sep 11, 25$87.47Sep 16, 25$82.35Sep 18, 25$85.84Sep 22, 25$84.62Sep 24, 25$82.79Sep 26, 25$79.92Sep 30, 25$81.55Oct 2, 25$84.49Oct 6, 25$86.62Oct 8, 25$87.59Oct 10, 25$82.56Oct 14, 25$85.32Oct 16, 25$85.33Oct 21, 25$75.88Oct 23, 25$75.26Oct 27, 25$75.68Oct 29, 25$77.09Oct 31, 25$88.07Nov 4, 25$85.95Nov 6, 25$81.79Nov 10, 25$88.35Nov 12, 25$92.61Nov 14, 25$90.03Nov 18, 25$91.64Nov 20, 25$95.20Nov 25, 25$104.35Nov 28, 25$106.29Dec 2, 25$106.07Dec 4, 25$108.85Dec 8, 25$108.46Dec 10, 25$108.72Dec 12, 25$108.88Dec 16, 25$113.76Dec 18, 25$113.21Dec 22, 25$117.09Dec 24, 25$116.64Dec 29, 25$115.55Jan 2, 26$110.72Jan 6, 26$112.28Jan 8, 26$114.15Jan 12, 26$110.91Jan 14, 26$104.43Jan 16, 26$120.24Jan 21, 26$124.16Jan 23, 26$119.98Jan 27, 26$118.70Jan 29, 26$119.07Feb 2, 26$117.47Feb 4, 26$114.67Feb 9, 26$113.27Feb 11, 26$109.03Feb 13, 26$109.47Feb 18, 26$121.00Feb 20, 26$120.27Feb 24, 26$119.17Feb 26, 26$121.43Mar 2, 26$121.12Mar 4, 26$115.37Mar 6, 26$107.73Mar 10, 26$103.15Mar 12, 26$97.79Mar 17, 26$102.93Mar 19, 26$102.09Mar 23, 26$106.84Mar 25, 26$109.60Mar 27, 26$103.18Mar 31, 26$107.66Apr 2, 26$112.77Apr 7, 26$115.06Apr 9, 26$119.45Apr 13, 26$119.49Apr 15, 26$121.00Apr 17, 26$124.79Apr 22, 26$121.65Apr 24, 26$121.48Apr 28, 26$119.63Apr 30, 26$143.67May 4, 26$135.85May 6, 26$135.27May 8, 26$133.52May 12, 26$136.36May 14, 26$142.15May 18, 26$142.18May 20, 26$143.82May 22, 26$120.23May 28, 26$106.52Jun 1, 26$103.12Jun 3, 26$113.64Jun 5, 26$125.00Jun 9, 26$126.34Jun 11, 26$124.26Jun 15, 26$130.14Jun 17, 26$127.41Jun 22, 26$131.19Jun 24, 26$137.76Jun 26, 26$144.42Jul 2, 26$148.34
$74.6752-week range$148.34
Loading valuation history…

Fundamentals

Key fundamentals

$6.1B

Market cap

32.3%

Revenue growth (YoY)

77.5%

Gross margin

-$54M

Free cash flow (USD)

-$139.1M

Net debt

Net cash position

8.4%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$114.4MFY 2017$159.3MFY 2018$181.3MFY 2019$237.0MFY 2020$225.0MFY 2021$294.0MFY 2022$282.9MFY 2023$314.7MFY 2024$383.5MFY 2025$507.4M
$114.4M$507.4M

Free cash flow by year

2016 → 2025

FY 2016$6.0MFY 2017$19.2MFY 2018$8.5MFY 2019$-5.1MFY 2020$-29.9MFY 2021$-23.1MFY 2022$-63.3MFY 2023$-78.0MFY 2024$-67.6MFY 2025$-54.0M
$6M-$54M

Gross margin by year

2021 → 2025

FY 202177.3%FY 202275.6%FY 202376.0%FY 202475.5%FY 202577.5%
77.3%77.5%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

7

Insider sells · 90 days

Earnings

Last report: 10-Q filed Apr 30, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $201K · 10b5-1 PlanNavratil Tomas · CHIEF DEVELOPMENT OFFICER · $200.9KJun 18, 2026Filing
  • 8-K eventAnnual Meeting ResultsJun 3, 2026Filing
  • Insider sellInsider Sell $704KKliman Gilbert H · Director · $703.8KMay 18, 2026Filing
  • Insider sellInsider Sell $675KKliman Gilbert H · Director · $675KMay 13, 2026Filing
  • Insider sellInsider Sell $244KWEN LEANA · Director · $243.7KMay 4, 2026Filing
  • Insider sellInsider Sell $2.8MGilliam Joseph E · PRESIDENT & COO · $2.8MMay 4, 2026Filing
  • Insider sellInsider Sell $1.4M · 10b5-1 PlanThurman Alex R. · SVP & CHIEF FINANCIAL OFFICER · $1.4MMay 4, 2026Filing
  • 8-K eventInvestor Presentation ReleasedMay 4, 2026Filing
  • Quarterly report10-Q FiledApr 30, 2026Filing
  • 8-K eventEarnings ReleaseApr 29, 2026Filing

Questions

Frequently asked questions

What is Glaukos Corporation's market cap?

Glaukos Corporation (GKOS) has a market capitalization of $6.1B.

What is GKOS's P/E ratio?

A meaningful P/E ratio is not available for GKOS — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is GKOS's price-to-book (P/B) ratio?

GKOS trades at 9.35 times book value per share.

Are insiders buying GKOS stock?

SEC Form 4 filings show no open-market insider buys at Glaukos Corporation in the last 90 days (7 sells).

Same arena

Related companies in Medical - Devices

LIVN

LivaNova PLC

$4B

IRTC

iRhythm Technologies, Inc.

$3.8B

BIO

Bio-Rad Laboratories, Inc.

$8.5B

BRKR

Bruker Corporation

$8.8B

ITGR

Integer Holdings Corporation

$3.1B

MASI

Masimo Corporation

$9.3B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.